NOVOCURE INC.

Lobbying client · Pennsylvania · filed 2025 to 2026

$780,000 Reported spend

6 Filings counted

1 Firms hired

4 Bills named

Spend is reported income plus in-house expenses across 6 filings. Everything on this page is grouped by the client's LDA id (213758), not by name.

Firms hired 1

NOVOCURE INC. $780,000 6 filings

Bills named in these filings 4

S 1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025

5 filings
HR 5343
Ensuring Patient Access to Critical Breakthrough Products Act

4 filings
HR 1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024

1 filing
S 5349
Ensuring Patient Access to Critical Breakthrough Products Act of 2024

1 filing

Reported by year 2 years

2026 $340,000 2 filings
2025 $440,000 4 filings

Issues lobbied 3

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 5

Health & Human Services, Dept of (HHS) 6
HOUSE OF REPRESENTATIVES 6
SENATE 6
Commerce, Dept of (DOC) 1
U.S. Trade Representative (USTR) 1

Recent filings 6 total

Q2

NOVOCURE INC.

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $160,000 expenses · posted Jul 19, 2026

View → Q1

NOVOCURE INC.

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $180,000 expenses · posted Apr 20, 2026

View → Q4

NOVOCURE INC.

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $110,000 expenses · posted Jan 17, 2026

View → Q3

NOVOCURE INC.

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $110,000 expenses · posted Oct 13, 2025

View → Q2

NOVOCURE INC.

2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $110,000 expenses · posted Jul 15, 2025

View → Q1

NOVOCURE INC.

1st Quarter (Jan 1 - Mar 31) 2025 · House · Senate · $110,000 expenses · posted Apr 16, 2025

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.